Dr Paula Wells oncology training was undertaken at St. Bartholomew's, UCLH, and Mount Vernon Hospitals; following her Fellowship, she undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There she investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue for which she received a number of awards. She has published a number of papers in this area and was awarded a Ph.D. for her work. Subsequently, she completed her post-doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.

Dr Wells specializes in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies and has expertise in all non-surgical treatments including chemotherapy, immunotherapy, biological and targeted therapies. She utilises state-of-the-art radiotherapy techniques including image-guided (IGRT), intensity-modulated radiotherapy (IMRT), 4D CT, and Stereotactic Radiotherapy (SABR and SRS) using both Cyberknife and Linear accelerator platforms. In addition, she has extensive experience of low dose rate brachytherapy (LDR) in the management of prostate cancer.

Since taking up her present NHS post she has been extensively involved with the development of the genitourinary and thoracic cancer services for the North East London Cancer Network.

Dr Wells has an active trial portfolio of UK clinical trials and is the principal investigator for a number of pivotal radiotherapy studies. From these activities, she took a clinical lead in the development of IMRT for prostate cancer, chemo-radiation in bladder and lung cancer and Stereotactic Radiotherapy (SABR) at Barts Health. Her research interest in Positron Emission Tomography continues to develop with an emphasis on investigating the direct effects of radiotherapy on tissue and the integration of novel therapies with radiation. She is currently Clinical Governance and Audit Lead for Barts Cancer Centre and Chairs the Stereotactic Body MDT.

Diseases, Medical Tests and Treatments

• Urological (bladder, prostate)
• Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)
• Urological (bladder, prostate)
• Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)